Showing results (181-190 of 275) with videos related to
Sort By:
Pageof 28
Blood Advances|April 12, 2022
A complex proinflammatory cascade mediates the activation of HSCs upon LPS exposure in vivoUta Margareta Demel, Raphael Lutz, Stefanie Sujer, et al.Pancreas|September 26, 2025
Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDACVera Thiel, Wiebke M Nadler, Alexander Kerner, et al.Science Translational Medicine|November 9, 2018
Wnt1 is an Lrp5-independent bone-anabolic Wnt ligandJulia Luther, Timur Alexander Yorgan, Tim Rolvien, et al.Cell|April 17, 2026
Cancer neuroscience: The past, the present, and the road aheadFrank Winkler, Sophie Heuer, Ferdinand Althammer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2017
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment ResponseAlexander Muckenhuber, Anne Katrin Berger, Anna Melissa Schlitter, et al.Blood|June 20, 2020
Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cellsSimon Raffel, Daniel Klimmeck, Mattia Falcone, et al.Journal of Innate Immunity|December 9, 2025
Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory ArthritisFranca Sophie Deicher, Tarik Exner, Maren Claus, et al.Oncoimmunology|January 27, 2017
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinomaIsabel Poschke, Marta Faryna, Frank Bergmann, et al.Proceedings of the National Academy of Sciences of the United States of America|January 21, 2018
Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumorsMagdolna Djurec, Osvaldo Graña, Albert Lee, et al.Aging|November 8, 2015
A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibitionClemens Stockklausner, Simon Raffel, Julia Klermund, et al.Pageof 28